Cardiothoracic Anesthesia and Critical Care in the United Kingdom (UK) Part 1: Some Insights Into the History and Development
- PMID: 33726943
- DOI: 10.1053/j.jvca.2021.02.030
Cardiothoracic Anesthesia and Critical Care in the United Kingdom (UK) Part 1: Some Insights Into the History and Development
Abstract
This review is intended to highlight some of the historic events that contributed to the development of thoracic and cardiac anesthesia and surgery in Great Britain and Northern Ireland (UK). The aim of this first of two parts is to concentrate on the development of techniques, facilities, and pharmacology that allowed progress and advancement in patient management that were developed primarily in the UK. However, progress usually requires input from a wide variety of sources of knowledge, and cardiothoracic practice is no exception. Reference is, thus, made to sources outside of the UK that guided, influenced, or inspired changes in practice, such as the techniques of operating on the heart and great vessels in war casualties, developed by Dr. Dwight Harken, or the demonstration of the Blalock-Thomas-Taussig shunt by Alfred Blalock. In addition to advances in medical equipment, such as computed tomography, the UK contributed greatly to pharmacologic interventions that were unique at the time in such varied areas as nonflammable volatile anesthetic agents, heart failure treatments, and neuromuscular blocking agents for both cardiac and thoracic surgical practice.
Keywords: aprotinin; cardiopulmonary bypass history; development of neuromuscular blocking agents; historic development of cardiothoracic anesthesia and surgery; lung separation; nonflammable volatile anesthetic agents; treatment for heart failure.
Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest David Royston was a consultant to Bayer Shering Pharma at their meetings with the Food and Drug Agency in the United States of America in September 2006 and October 2007 and with the European Medicines Agency in October 2010. He is a member of the Data Safety Monitoring Committee of the Nordic Aprotinin Patient Registry (NAPaR). R Peter Alston was an independent expert adviser to the aprotinin review held by the European Medicines Agency.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources